Denosumab increases sublesional bone mass in osteoporotic individuals with recent spinal cord injury.

Treatment with denosumab increases lumbar and femoral BMD and decreases bone turnover markers in individuals with recent SCI. This drug may be a promising therapeutic option in SCI-related osteoporosis.